FDA Halts Rocket Pharmaceuticals' Gene Therapy Trial After Patient Death
TL;DR Summary
A participant in Rocket Pharmaceuticals' gene therapy trial for Danon disease died, with the company investigating the cause, possibly related to immune suppression drugs used before therapy.
Topics:business#clinical-trial#danon-disease#gene-therapy#health#patient-death#rocket-pharmaceuticals
- Participant in Rocket Pharmaceuticals gene therapy study dies statnews.com
- FDA halts Rocket Pharma's gene therapy trial as patient dies Reuters
- Gene Therapy Death Worsens Picture for an Already Troubled Field Barron's
- Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Business Wire
- Rocket crashes as gene therapy patient dies, FDA imposes hold Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
89%
252 → 27 words
Want the full story? Read the original article
Read on statnews.com